About US
Contact us
-
Valeant reportedly holding talks to divest gastrointestinal treatment specialist businessValeant Pharmaceuticals is reportedly holding advanced talks to divest its gastrointestinal treatment specialist business to Japanese firm Takeda Pharmaceutical for approximately $10bn. According to2016/11/3
-
Medivir to sell BioPhausia to Karo PharmaMedivir has entered into an agreement to sell its subsidiary BioPhausia (Nordic Brands) to Karo Pharma forSkr908m ($100.9m). This price will be on a cash and debt free basis, including a normalised w2016/11/2
-
Astellas to acquire German company Ganymed Pharmaceuticals for €1.2bnJapan’s Astellas Pharma has signed an agreement to acquire German-based biopharmaceutical company Ganymed Pharmaceuticals for €1.2bn. With this transaction, Astellas will be able to continue to build2016/11/2
-
EMA validates MAA for avelumab for treatment of metastatic merkel cell carcinomaThe European Medicines Agency (EMA) has validated for review Merck KGaA's marketing authorisation application (MAA) for avelumab, for the proposed indication of metastatic merkel cell carcinoma (MCC).2016/11/1
-
Novartis LEE011 receives FDA Priority Review for first-line treatment of HR+ / HER2- advanced breast cancerThe US Food and Drug Administration (FDA) has accepted Novartis' New Drug Application (NDA) for filing and granted Priority Review for LEE011 (ribociclib) as first-line treatment of postmenopausal wom2016/11/1
-
Drug flippers exploit pharma's price-hike climate for fast profitHefty drug price increases have been an outrage-provoking subject for politicians, the public and pharmacy benefits managers all year long. But another group besides drugmakers hasbeen benefiting from2016/10/31
-
Hot immuno-oncology combos can trigger rare but fatal heart damage: NEJMTwo prominent doctors have flagged a serious and unexpected side effect linked to the immuno-oncology drugs taking cancer treatment by storm: heart damage that can be fatal. In aNew England Journal o2016/10/31
-
Eisai wins NICE backing for older Halaven but still isn't happy about LenvimaAfter weighing new data and a discount, England’s drug-cost watchdogsbackedEisai’s Halavento treat advanced breast cancer, making it the first drugto win a green lightin breast cancer in nearly a deca2016/10/28
-
Why is Valeant's 'blockbuster' libido drug Addyi a dud? Shoddy marketing, investor lawsuit claimsWhen Valeant bought Sprout Pharmaceuticals and its controversial female libido drug Addyi, it agreed to a marketing blitz that would bring royalties to Sprout's former shareholders. Valeant bungled th2016/10/28
-
Allergan's handling of Q3 'black eye' dings confidence in management: AnalystAllergan’s third-quarter numbersweren’t good. But neither was the way the company talked about them, one analyst says, and that’s even more worrisome. On Wednesday, Allergan disclosed that revenue ha2016/10/27